PCM
BIO icon

Penserra Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Penserra Capital Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-96
Closed -$30K – 1262
2023
Q4 		$30K Sell
96
-20
-17% -$6.27K ﹤0.01% 1058
2023
Q3 		$41K Sell
116
-24
-17% -$9.26K ﹤0.01% 1020
2023
Q2 		$53K Buy
+140
New +$57K ﹤0.01% 1030
2020
Q2 		– Sell
-800
Closed -$365K – 808
2020
Q1 		$365K Buy
+800
New +$294K 0.02% 372

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Penserra Capital Management's BIO Position: Q1 2024 in Review

Penserra Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2024, closing a stake of 96 shares — an estimated $30K sold.

Penserra Capital Management first reported a position in BIO in Q1 2020 and held it in 4 quarters. The position peaked at $365K in Q1 2020. 467 funds tracked by Wall St. Rank hold BIO as of Q1 2024.

  • Penserra Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q1 2024 after selling out during the quarter.
  • Penserra Capital Management sold 96 Bio-Rad Laboratories Class A shares in Q1 2024, an estimated $30K.
  • Penserra Capital Management first reported a position in Bio-Rad Laboratories Class A in Q1 2020 and held it in 4 quarters.
  • Penserra Capital Management's Bio-Rad Laboratories Class A position peaked at $365K in Q1 2020.
  • 467 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2024.

Based on Penserra Capital Management's 13F filing for Q1 2024, filed 15 May 2024.